Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Maurey, P. Henno, C. Delclaux, P. Bonnette, D. Israel-biet, M. Levy (Paris, Suresnes, France). Endothelial dysfunction in cystic fibrosis: imbalance NOS/arginase?. Eur Respir J 2007; 30: Suppl. 51, 2662

Member's Comments

No comment yet.

Related content which might interest you: Role of endothelin-1 in endothelial dysfunction in cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Premature vascular ageing in cystic fibrosis Source: Eur Respir J 2009; 34: 1217-1218 Year: 2009 PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis Source: ERS Lung Science Conference 2021 Year: 2021 Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? Source: Eur Respir J, 56 (4) 2003167; 10.1183/13993003.03167-2020 Year: 2020 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Skeletal muscle metabolism in active cystic fibrosis (CF) patients with light/moderate pulmonary dysfunction Source: International Congress 2015 – Clinical exercise physiology in health and disease Year: 2015 Regular exercise improves airway inflammation in cystic fibrosis patients Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Clinical correlation of epithelial barrier dysfunction related to neutrophilic inflammation in cystic fibrosis Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Neomacrolides in cystic fibrosis Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease Year: 2012 Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients Source: Eur Respir J 2010; 36: 682-683 Year: 2010 Early signs of MMP/TIMP imbalance in cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 8s Year: 2001 Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Nutritional intervention in cystic fibrosis Source: ISSN=1025-448x, ISBN=1-904097-27-8, page=153 Year: 2003 Regulation of interleukin-8 by miR-17 during chronic inflammation in cystic fibrosis Source: International Congress 2015 – The multiple faces of host defense Year: 2015 Airway inflammation in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 14-31 Year: 2014 Epithelium involvement and remodeling of interstitium in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006 LATE-BREAKING ABSTRACT: A relative plasma Elafin deficiency in children with cystic fibrosis (CF) is associated with pulmonary disease Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013